Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis

Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.

Download Full-text

Antibody Therapy in Aggressive Lymphomas

Hematology ◽

10.1182/asheducation-2007.1.257 ◽

2007 ◽

Vol 2007 (1) ◽

pp. 257-264 ◽

Cited By ~ 4

Author(s):

Thomas M. Habermann

Keyword(s):

Monoclonal Antibody ◽

T Cell ◽

Natural History ◽

B Cell ◽

Antibody Therapy ◽

Lymphoproliferative Disorders ◽

Monoclonal Antibody Therapy ◽

Aggressive Lymphomas ◽

History Of ◽

Anti Cd20

AbstractThe aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in patients who have relapsed and in stem cell transplant settings. Antibody-directed therapy to the B-cell–specific antigen CD22 are ongoing. New approaches include different CD20 antibodies and an antibody to the CD40 antigen, which is a member of the tumor necrosis factor (TNF) receptor family, which is expressed on B-cells. Antibody therapy has been incorporated into CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) therapy and other regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) and HyperCVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone). Single-agent anti-CD20 therapy is active in the post-transplantation lymphoproliferative disorders. T-cell antibodies are under evaluation in a number of T-cell lymphoproliferative disorders. Targeted therapy has changed the natural history of a number of aggressive non-Hodgkin lymphomas. This review will describe the contributions of antibody therapies to the treatment of these diseases.

Download Full-text

MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial

Clinical Rheumatology ◽

10.1007/s10067-017-3956-3 ◽

2018 ◽

Vol 37 (4) ◽

pp. 917-925

Author(s):

Xiaoxia Yu ◽

Lei Zhang ◽

Lixin Wang ◽

Weiwei Lu ◽

Fengyan Sun ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Randomized Controlled ◽

Double Filtration Plasmapheresis ◽

Double Filtration

Download Full-text

Anti-CD20 monoclonal antibody therapy in Epstein-Barr virus–associated B cell lymphoma following lung transplantation

The Journal of Heart and Lung Transplantation ◽

10.1016/s1053-2498(00)00087-5 ◽

2000 ◽

Vol 19 (5) ◽

pp. 492-495 ◽

Cited By ~ 14

Author(s):

Martine Reynaud-Gaubert ◽

Anne Marie Stoppa ◽

Jean-Yves Gaubert ◽

Pascal Thomas ◽

Pierre Fuentes

Keyword(s):

Monoclonal Antibody ◽

B Cell ◽

Epstein Barr Virus ◽

Cell Lymphoma ◽

Antibody Therapy ◽

B Cell Lymphoma ◽

Monoclonal Antibody Therapy ◽

Barr Virus ◽

Epstein Barr ◽

Anti Cd20

Download Full-text

Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients.

Blood ◽

10.1182/blood.v104.11.3250.3250 ◽

2004 ◽

Vol 104 (11) ◽

pp. 3250-3250

Author(s):

Wen-Kai Weng ◽

Abby Rosenberg ◽

Ronald Levy

Keyword(s):

Follicular Lymphoma ◽

Predictive Value ◽

Clinical Course ◽

Antibody Therapy ◽

B Cell Lymphoma ◽

Fc Receptor ◽

Time Interval ◽

Low Grade ◽

Response To Chemotherapy ◽

Anti Cd20

Abstract Patients with low-grade B cell lymphoma, such as follicular lymphoma usually have an indolent clinical course. In most of the cases, patients do not require therapy at the time of diagnosis. Instead, patients can be monitored from months to years before the need for therapy. However, the time interval from diagnosis to the first therapy in these patients can vary significantly. In addition, the overall clinical course is heterogeneous in these patients with variable length of survival after diagnosis. The pathobiological basis of this hetergenisity is not known. We have recently found that IgG Fc receptor (FcγR) polymorphisms correlated with clinical outcome after immunotherapies in patients with follicular lymphoma. In one case, FcγRIIIa 158 V/F and FcγRIIa 131 H/R polymorphisms predicted the response to anti-CD20 antibody, rituximab therapy probably due to their role in the antibody-dependent cellular cytotoxicity. One question is whether the FcγR polymorphisms are correlated with the general clinical course of follicular lymphoma due toq their role in innate immunity. We therefore tested if FcγRIIIa 158 V/F, FcγRIIa 131 H/R and FcγRIIb 232 I/T polymorphisms predict clinical course of a group of 307 patients with follicular lymphoma. None of the three FcγR polymorphisms tested correlated with the time interval from diagnosis to first therapy, or with overall survival in this group of patients. We then tested whether FcγR polymorphisms have predictive value on clinical response to chemotherapy. Of 307 patients, only 158 patients received chemotherapy alone as first therapy, while the rest of the patients have received additional idiotype vaccination or rituximab. In the analysis of these 158 patients, there was no correlation between the FcγR polymorphisms and response rate to chemotherapy or time to progression after chemotherapy. Our results did not find any association between the three FcγR polymorphisms tested and clinical course of disease or response to chemotherapy in patients with follicular lymphoma, suggesting that the predictive value of FcγR polymorphisms on the clinical responses to rituximab is specific to the monoclonal antibody therapy.

Download Full-text